Company overview
GeneDx provides comprehensive genetic testing including whole exome sequencing, whole genome sequencing, and targeted panels for diagnosing rare and complex conditions in pediatric and adult populations. For biopharma, GeneDx offers GeneDx Infinity™, a genomic data platform with the largest rare disease dataset, over 2.5M genetic tests, 1M+ exomes and genomes, and deep phenotypic data linked to claims for real-world evidence. This supports drug discovery, development, and patient journey analysis in life sciences and pharma.
Genedx is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include genedx, genetic testing, whole exome sequencing, whole genome sequencing, rare disease genomics, biopharma data platform.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.genedx.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- genedx, genetic testing, whole exome sequencing, whole genome sequencing, rare disease genomics, biopharma data platform
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What genetic testing capabilities does GeneDx offer for rare disease diagnosis?
- GeneDx offers whole exome sequencing (WES), whole genome sequencing (WGS), and targeted panels to identify variants in rare and complex conditions like developmental delay, epilepsy, autism, and congenital anomalies across pediatric and adult patients.
- What is GeneDx Infinity™ and how does it support biopharma R&D?
- GeneDx Infinity™ is the largest rare disease genomic dataset with ~2.5M genetic tests, 1M+ exomes/genomes sequenced, 8M+ structured phenotypic data points, and claims data, enabling longitudinal patient journey analysis for drug discovery and real-world evidence.
- What are GeneDx's regulatory and clinical expertise highlights?
- GeneDx has 25+ years in rare-disease diagnostics, powers clinical genomic testing with industry-leading WES/WGS, and collaborates on advanced technologies like Illumina's constellation mapped reads and PacBio long-read sequencing for improved variant detection.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
